• Users Online: 42
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 
Year : 2010  |  Volume : 2  |  Issue : 1  |  Page : 32-37

Anemia in chronic heart failure: A review

1 Department of Medicine, Gradiot Medical Center, MI, USA
2 Department of Medicine, The Ohio State University, Columbus, Ohio, USA

Correspondence Address:
A E Faraj
Department of Medicine, Gradiot Medical Center, MI
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1947-489X.210966

Rights and Permissions

Despite advances in chronic heart failure (CHF) medical and device therapy in recent years, CHF continues to be a syndrome associated with significant morbidity and mortality. Abundance of data suggests that anemia is prevalent in CHF. The pathophysiology of CHF-related anemia is complex and poorly understood. Earlier small trials demonstrated improvement in morbidity with use of erythropoietin stimulating agents (ESA) and parenteral iron but that was not supported by more recent large randomized trials. There is a concern regarding the safety of ESA. Small studies showed benefits from parenteral iron alone or combination with ESA. This was promising since parenteral iron is a relatively cheap therapeutic intervention to treat anemia in CHF patients. So far there are no clear recommendations regarding the treatment of CHF related anemia. The purpose of this article is to review the most recent epidemiology, pathophysiology, and therapeutic options for anemia in CHF.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded84    
    Comments [Add]    

Recommend this journal